HOLON, Israel, May 5, 2025
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:
CGEN), a clinical-stage cancer immunotherapy company and a pioneer
in computational target discovery, today announced that the
Company will release its first quarter 2025 financial results on
Monday, May 19, 2025, before the U.S.
financial markets open. Management will host a conference call and
webcast to review the results and provide a corporate update at
8:30 AM ET.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via
live webcast through Compugen's website, which is located at the
following link. Following the live webcast, a replay will be
available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery platform (Unigen™) to identify
new drug targets and biological pathways for developing cancer
immunotherapies. Compugen has two proprietary product candidates in
Phase 1 development: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT component is derived
from Compugen's clinical stage anti-TIGIT antibody, COM902, is in
Phase 3 development by AstraZeneca through a license agreement for
the development of bispecific and multispecific
antibodies. GS-0321 (previously COM503), a potential
first-in-class, high affinity anti-IL-18 binding protein antibody,
which is in Phase 1 development is licensed to Gilead. In addition,
the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of research
programs aiming to address various mechanisms to enhance
anti-cancer immunity. Compugen is headquartered in
Israel, with offices in
San Francisco, CA. Compugen's
shares are listed on Nasdaq and the Tel Aviv Stock Exchange
under the ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2025-results-on-monday-may-19-2025-302445841.html
SOURCE Compugen Ltd.